Trump's Tylenol-Autism Claims Spark Backlash from Medical Community

President Donald Trump's recent statements linking the use of Tylenol (acetaminophen) during pregnancy to autism have drawn significant criticism from medical professionals and researchers. During a White House press conference on September 22, 2025, Trump advised pregnant women to avoid Tylenol, suggesting a potential connection to autism—a claim not supported by scientific evidence.

Medical organizations, including the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists, have refuted these assertions. Dr. Steven Fleischman, president of the ACOG, stated that suggestions linking acetaminophen use in pregnancy to autism are "highly concerning to clinicians" and "irresponsible" due to the lack of supporting scientific evidence.

Experts emphasize that acetaminophen remains one of the safest options for managing pain and fever during pregnancy. Dr. Nicole Saphier noted that while caution with medication is prudent, untreated pain or fever poses serious risks to both mother and baby.

The Trump administration also announced efforts to increase the availability of leucovorin (folinic acid) as a potential treatment for autism, despite the lack of conclusive research supporting its efficacy.

Internationally, South Korea's drug regulatory authority has initiated a review in response to the U.S. statements, seeking information from pharmaceutical companies to assess the situation.

Medical professionals and researchers continue to stress the importance of relying on established scientific evidence when making health recommendations, particularly concerning medications during pregnancy.